Wells Fargo & Company An2 Therapeutics, Inc. Transaction History

Wells Fargo & Company

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$2.78 - $21.53 $5 - $43	2 Added 1.59%	128 $0
Q4 2023 Feb 09, 2024	BUY	$13.92 - $21.0 $890 - $1,344	64 Added 103.23%	126 $2,000
Q3 2023 Nov 13, 2023	BUY	$7.58 - $16.08 $204 - $434	27 Added 77.14%	62 $0
Q2 2023 Aug 15, 2023	SELL	$5.06 - $9.91 $9,770 - $19,136	-1,931 Reduced 98.22%	35 $0
Q1 2023 May 12, 2023	BUY	$7.94 - $15.6 $15,610 - $30,669	1,966 New	1,966 $19,000
Q3 2022 Nov 14, 2022	SELL	$7.61 - $22.29 $350 - $1,025	-46 Reduced 63.01%	27 $0
Q2 2022 Aug 12, 2022	BUY	$7.7 - $18.82 $562 - $1,373	73 New	73 $1,000

13.5M

Ticker ANTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 19,402,700
Market Cap $27.9M
Description
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menl...

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

Stay updated on Wells Fargo & Company with notifications on news.